What This MannKind Director Sale Signals With $32.7 Million in Quarterly Royalties Revenue Potentially at Risk
Binder's disposition followed vesting of performance-based awards tied to the company's total shareholder return relative to the Russell 3000 Pharmaceutical & Biotechnology Index.
Overview
Director Steven B. Binder disclosed a disposition of 76,880 shares of MannKind Corporation (NASDAQ:MNKD) at $4.07 per share in transactions completed on July 15, 2026, and July 17, 2026, according to a recent SEC Form 4 filing.
Transaction value based on SEC Form 4 weighted average sale price ($4.07); post-transaction value based on July 17, 2026 market close ($4.03).
Details
MannKind Corporation is a biopharmaceutical company with a market capitalization of $1.2 billion and TTM revenue of $360.8 million. The company's competitive differentiation derives from its innovative pulmonary delivery technology platform, which enables non-invasive administration of therapeutics for endocrine disorders and rare lung conditions. MannKind's strategic focus on respiratory-delivered treatments addresses significant unmet medical needs while positioning the company within the specialized biopharmaceutical sector.
Source
Originally published at www.fool.com.